Home › Autoimmune Diseases › Ohio › Columbus
Autoimmune Diseases clinical trials in Columbus, OH
4 studies for Autoimmune Diseases are looking for participants at sites in and around Columbus (within about 30 miles). Open a study to see who can join and how to contact the study team.
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingPhase 1
- Ohio State University Comprehensive Cancer Center, Columbus
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecruitingObservational study
- Nationwide Children's Hospital, Columbus
- The Arthur G. James Cancer Hospital/The Ohio State University Medical Center, Columbus
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
RecruitingPhase 1
- Ohio State University, Columbus
IMPACT - AndHealth Autoimmune Research Registry
RecruitingObservational study
- AndHealth, Columbus
About Autoimmune Diseases
Autoimmune diseases are where your immune system attacks healthy cells in your body by mistake. Learn about the symptoms, tests, and treatments.
More about Autoimmune Diseases on MedlinePlus
Autoimmune Diseases trials in other cities
- Houston, TX21 studies
- New York City, NY19 studies
- Washington, DC19 studies
- Philadelphia, PA16 studies
- Durham, NC15 studies
- Boston, MA13 studies
- Los Angeles, CA12 studies
- Chicago, IL12 studies
- Dallas, TX9 studies
- Atlanta, GA8 studies
- Milwaukee, WI8 studies
- Cleveland, OH8 studies
Other studies in Columbus
- Non-Small Cell Lung Cancer54 studies
- Ovarian Cancer40 studies
- Breast Cancer39 studies
- Cancer (all types)39 studies
- Lung Cancer36 studies
- Acute Myeloid Leukemia34 studies
- Chronic Lymphocytic Leukemia29 studies
- Endometrial Cancer26 studies
- Metastatic Cancer26 studies
- Multiple Myeloma24 studies
- Prostate Cancer24 studies
- Colorectal Cancer23 studies
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.